(b) whether it is also a fact that there are more than five producers of bulk drug and more than ten formulators;

(c) whether it is also a fact that process to manufacture this drug has been developed indigenously; and

(d) whether this drug will be price decontrolled?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) Sales turn over of formulations is not monitored.

(c) and (d) Applications received from various companies seeking exemption of different bulk drugs from price control on this ground are under consideration.

**Price control on Paracetamol**

1451. SHRI BEKAL UTSAHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 140 given in the Rajya Sabha on the 24th April, 1989 and state:

(a) whether it is a fact that Paracetamol fulfils all the exclusion criteria;

(b) whether it is also a fact that none of the formulators account for turnover of more than 23 per cent;

(c) whether his Ministry has examined the comparison of concentration of Paracetamol to Glybenclomide;

(d) if so, what are the details thereof; and

(e) what steps have been taken by his Ministry to rectify these discrepencies?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) After considering various representations, the Kelkar Committee, in its Supplementary Report, has recommended shifting of Paracetamol from Schedule I of DPCO, 1987 to Schedule II and exemption of Glybenclamide from price control under DPCO 1987. These recommendations of the Kelkar Committee have been accepted by the Government.

**Price of Aspirin.**

1452. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) when were the recommendations regarding fair price of Aspirin received from SICP;

(b) when was the price fixed by his Ministry;

(c) whether his Ministry fixed any ad hoc price;

(d) if so, on whose recommendations; and

(e) what are the reasons for not referring the matter of fixation of ad hoc price to BICP?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) The price of Aspirin bulk drug was revised to Rs. 80/- per kg. on "ad hoc" basis with effect from 2.6.1988 consequent on the representations received from the manufacturers of this drug. However, the Cost Price study of this drug was simultaneously taken up by the BICP and on the basis of BICP Report received in November 1988 a price of Rs. 71/- per kg. has been fixed with effect from 20.1.1989 on their recommendations.

**Price control on Vitamin B6**

1453. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that Vitamin B6 is being produced from inermediate stage by certain producers;

(b) what are the names of producers of Vitamin B6 and what is the stage of production of each;